4//SEC Filing
Decheng Capital China Life Sciences USD Fund III, L.P. 4
Accession 0001209191-24-002016
CIK 0001626199other
Filed
Jan 21, 7:00 PM ET
Accepted
Jan 22, 6:54 PM ET
Size
9.8 KB
Accession
0001209191-24-002016
Insider Transaction Report
Form 4
Transactions
- Exercise of In-Money
Common Stock
2024-01-18$12.74/sh+1,234,636$15,729,263→ 6,582,380 total - Exercise of In-Money
Warrant (right to buy)
2024-01-18−1,234,636→ 0 totalExercise: $12.74From: 2019-01-18Exp: 2024-01-18→ Common Stock (1,234,636 underlying)
Footnotes (1)
- [F1]The reportable securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Xiangmin Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. GP III disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports.
Documents
Issuer
ALPINE IMMUNE SCIENCES, INC.
CIK 0001626199
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001736814
Filing Metadata
- Form type
- 4
- Filed
- Jan 21, 7:00 PM ET
- Accepted
- Jan 22, 6:54 PM ET
- Size
- 9.8 KB